论文部分内容阅读
40年前Fletcher等首先应用链激酶(Streptokinase,SK)治疗早期急性心肌梗死(AMI),进入80年代,溶栓治疗已成为AMI的常规疗法。据估计每年有超过50万的患者接受溶栓治疗,而至少超过3倍于此的曾接受该治疗的患者从中受益。同时,溶栓药物的研究发展迅速,目前常用的溶栓药物有链激酶,尿激酶(urokinase,UK),重组组织型纤溶酶原激活剂(recombinant tissue-type plasminogen activator,r-tPA),茴香酰纤溶酶原链激酶复合物(Anisoykated plasminogenstreptokinase activator complex,APSAC),重组单链尿激酶型纤溶酶原激活剂(recombinant-sin-
Forty years ago, Fletcher et al. First used streptokinase (SK) in the treatment of early acute myocardial infarction (AMI). In the 1980s, thrombolytic therapy has become the routine therapy of AMI. It is estimated that more than 500,000 patients receive thrombolytic therapy each year, while patients who have received the treatment for at least three times more benefit from it. At the same time, the research of thrombolytic drugs is developing rapidly. Currently, the commonly used thrombolytic drugs are streptokinase, urokinase (UK), recombinant tissue-type plasminogen activator (r-tPA) Anisoykoplast plasminogenstreptokinase activator complex (APSAC), recombinant single-chain urokinase-type plasminogen activator (recombinant-sin-